Free tool
Oncology stocks
We cover 112 companies grouped under the Oncology theme. The median market value in the group is $808.87M. Across the group, the median move over the past trading day is −0.47%. 72% of the 108 with a 200-day average trade above it. Price change over the past year runs from −20.9% to +275.3% across the middle 80 percent of the group, with a median of +50.7%. Across the group, 3 companies currently carry a tier A volume signal.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
112 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $67.57 | +6.24% | +27.70% | +47.01% |
| RVMD | Revolution Medicines, Inc. | $215.44 | +17.18% | +172.64% | +466.35% |
| ONC | BeOne Medicines AG | $375.80 | +13.72% | +20.83% | +25.21% |
| BNTX | BioNTech SE | $112.56 | +21.75% | +16.41% | +9.27% |
| INCY | Incyte Corporation | $128.12 | −1.39% | +26.33% | +51.01% |
| GMAB | Genmab A/S | $33.75 | +16.38% | +6.07% | +36.20% |
| EXEL | Exelixis, Inc. | $56.10 | −0.73% | +28.73% | +45.68% |
| SMMT | Summit Therapeutics Inc. | $14.23 | +13.39% | −18.78% | −42.63% |
| NUVL | Nuvalent Inc | $123.96 | 0.00% | +22.93% | +62.83% |
| CGON | CG Oncology, Inc. | $78.42 | +7.99% | +87.65% | +196.15% |
| ERAS | Erasca, Inc. | $19.15 | +5.45% | +433.43% | +1112.03% |
| E2XE34.SA | Exelixis, Inc. | 137.40 BRL | −2.25% | +23.92% | +23.92% |
| LNTH | Lantheus Holdings, Inc. | $100.82 | −1.77% | +49.87% | +77.38% |
| COGT | Cogent Biosciences, Inc. | $36.72 | −9.71% | +5.70% | +196.85% |
| CELC | Celcuity Inc. | $95.08 | +15.30% | −5.44% | +90.31% |
| ELVN | Enliven Therapeutics, Inc. | $60.87 | +13.22% | +291.67% | +194.32% |
| TNGX | Tango Therapeutics, Inc. | $25.47 | −4.43% | +185.22% | +269.13% |
| RLAY | Relay Therapeutics, Inc. | $19.46 | +6.40% | +137.90% | +445.10% |
| IDYA | IDEAYA Biosciences, Inc. | $41.58 | +14.99% | +22.84% | +66.32% |
| RCUS | Arcus Biosciences, Inc. | $30.76 | +13.72% | +32.07% | +191.29% |
| TLX | Telix Pharmaceuticals Limited | $11.13 | +9.22% | +46.06% | −8.02% |
| IMNM | Immunome, Inc. | $28.75 | +23.82% | +38.09% | +188.94% |
| ZLAB | Zai Lab Limited | $26.03 | +39.80% | +50.20% | −20.06% |
| SLS | SELLAS Life Sciences Group, Inc. | $13.73 | +36.08% | +215.63% | +615.10% |
| NRIX | Nurix Therapeutics, Inc. | $26.71 | +10.60% | +47.90% | +179.69% |
| NUVB | Nuvation Bio Inc. | $6.96 | +4.04% | −18.88% | +135.93% |
| NBTX | Nanobiotix S.A. | $44.50 | +17.66% | +101.08% | +394.99% |
| URGN | UroGen Pharma Ltd. | $45.94 | +12.38% | +102.29% | +135.11% |
| HCM | HUTCHMED (China) Limited | $12.35 | +10.27% | −9.52% | −17.45% |
| XNCR | Xencor, Inc. Common Stock | $28.44 | +42.41% | +90.62% | +254.61% |
| ZYME | Zymeworks Inc. | $29.31 | +29.61% | +10.09% | +96.28% |
| NVCR | NovoCure Limited | $17.89 | +9.69% | +36.36% | +50.21% |
| IMCR | Immunocore Holdings plc | $37.12 | +10.77% | +9.89% | +13.69% |
| DMRA | Damora Therapeutics, Inc. | $30.39 | +3.30% | +39.28% | +804.46% |
| VIR | Vir Biotechnology, Inc. | $11.08 | +25.20% | +86.53% | +111.85% |
| INBX | Inhibrx Biosciences, Inc. | $125.34 | +57.30% | +67.03% | +357.45% |
| SNDX | Syndax Pharmaceuticals, Inc. | $20.09 | +2.34% | −5.68% | +23.55% |
| BCAX | Bicara Therapeutics Inc. | $24.73 | −8.00% | +50.98% | +105.74% |
| AAPG | Ascentage Pharma Group Internat | $16.90 | −7.57% | −35.91% | −59.18% |
| AVBP | ArriVent BioPharma, Inc. | $31.14 | +3.87% | +49.71% | +62.10% |
| REPL | Replimune Group, Inc. | $15.88 | +196.82% | +78.43% | +187.16% |
| CGEM | Cullinan Therapeutics, Inc. | $22.85 | +30.80% | +125.79% | +188.15% |
| AKTS | Aktis Oncology, Inc. | $26.51 | +15.41% | +18.35% | +18.35% |
| ORIC | ORIC Pharmaceuticals, Inc. | $13.91 | +16.79% | +70.26% | +35.58% |
| IMTX | Immatics N.V. | $9.43 | +7.96% | −9.76% | +74.63% |
| DRTS | Alpha Tau Medical Ltd. | $14.96 | +29.52% | +209.73% | +343.92% |
| GLUE | Monte Rosa Therapeutics, Inc. | $14.38 | −34.75% | −6.07% | +207.92% |
| CRVS | Corvus Pharmaceuticals, Inc. | $14.73 | +10.67% | +101.23% | +167.82% |
| KURA | Kura Oncology, Inc. | $13.06 | +40.28% | +26.37% | +66.16% |
| JANX | Janux Therapeutics, Inc. | $18.89 | +25.93% | +38.39% | −19.10% |
| CADL | Candel Therapeutics, Inc. | $13.28 | +37.19% | +144.12% | +124.70% |
| GERN | Geron Corporation | $1.53 | +5.52% | +15.91% | +8.51% |
| OLMA | Olema Pharmaceuticals, Inc. | $10.85 | −6.63% | −57.08% | +89.02% |
| ANL | Adlai Nortye Ltd. | $15.06 | +18.68% | +991.30% | +791.12% |
| RIGL | Rigel Pharmaceuticals, Inc. | $46.48 | +20.73% | +11.12% | +16.99% |
| NVCT | Nuvectis Pharma, Inc. | $25.00 | +26.14% | +193.77% | +275.94% |
| AURA | Aura Biosciences, Inc. | $7.73 | +9.65% | +45.85% | +20.03% |
| MNPR | Monopar Therapeutics Inc. | $113.72 | +4.24% | +72.28% | +226.69% |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $9.26 | +7.80% | −24.65% | −0.43% |
| CTMX | CytomX Therapeutics, Inc. | $3.32 | +3.11% | −21.88% | +60.39% |
| GUD.TO | Knight Therapeutics Inc. | 9.76 CAD | −0.81% | +65.14% | +50.39% |
| EIKN | Eikon Therapeutics, Inc. | $11.98 | +26.24% | −20.13% | −20.13% |
| SGMT | Sagimet Biosciences Inc. | $10.86 | +49.38% | +81.30% | +39.59% |
| CBIO | Crescent Biopharma, Inc. | $18.02 | +9.61% | +62.64% | +26.46% |
| VSTM | Verastem, Inc. | $7.39 | +18.62% | +2.21% | −20.45% |
| ARVN | Arvinas, Inc. | $9.32 | +13.66% | −18.74% | +15.35% |
| DCTH | Delcath Systems, Inc. | $16.40 | +41.99% | +64.82% | +49.91% |
| PRLD | Prelude Therapeutics Incorporated | $6.56 | +41.38% | +140.29% | +412.50% |
| CCCC | C4 Therapeutics, Inc. | $4.24 | +19.44% | +119.69% | +64.34% |
| TOI | Starling Oncology Inc | $6.20 | +25.25% | +68.94% | +79.19% |
| RLMD | Relmada Therapeutics, Inc. | $4.55 | −13.00% | +4.12% | +579.10% |
| PBYI | Puma Biotechnology, Inc. | $9.16 | +14.93% | +58.75% | +79.61% |
| CMPX | Compass Therapeutics, Inc. | $2.43 | +19.12% | −53.00% | −25.91% |
| FRX.TO | Fennec Pharmaceuticals Inc. | 17.00 CAD | +21.86% | +63.30% | +36.00% |
| FENC | Fennec Pharmaceuticals Inc. | $12.17 | +22.43% | +58.46% | +34.62% |
| GALT | Galectin Therapeutics Inc. | $4.15 | +22.42% | +2.47% | +4.27% |
| FHTX | Foghorn Therapeutics Inc. | $6.69 | +30.41% | +28.90% | +23.66% |
| AGEN | Agenus Inc. | $8.25 | +25.00% | +155.42% | +81.72% |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $3.89 | −15.80% | +183.94% | +113.74% |
| CATX | Perspective Therapeutics, Inc. | $3.16 | +10.10% | +13.26% | −12.47% |
| STRO | Sutro Biopharma, Inc. | $21.43 | −9.69% | +95.53% | +138.11% |
| IMRX | Immuneering Corporation | $5.15 | +21.46% | −22.21% | −0.77% |
| BCYC | Bicycle Therapeutics plc | $4.36 | +10.53% | −34.81% | −37.79% |
| PYXS | Pyxis Oncology, Inc. | $3.34 | +14.78% | +190.43% | +145.59% |
| WHWK | Whitehawk Therapeutics, Inc. | $4.84 | +31.52% | +98.36% | +167.40% |
| ALXO | ALX Oncology Holdings Inc. | $1.98 | −0.50% | +72.17% | +65.00% |
| CGEN | Compugen Ltd. | $2.84 | +25.66% | +83.23% | +93.20% |
| GLSI | Greenwich LifeSciences, Inc. | $18.23 | +35.54% | −6.37% | +56.21% |
| ADAG | Adagene Inc. | $3.85 | +3.22% | +109.24% | +75.80% |
| MGNX | MacroGenics, Inc. Common Stock | $4.04 | +4.94% | +150.93% | +134.88% |
| IPHA | Innate Pharma S.A. | $2.16 | +28.57% | +18.68% | +2.86% |
| TARA | Protara Therapeutics, Inc. | $3.91 | −0.76% | −27.32% | +21.05% |
| CHRS | Coherus Oncology, Inc. | $1.45 | +0.69% | +5.84% | +27.19% |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $11.30 | +24.38% | +43.58% | +7.93% |
| NBP | NovaBridge Biosciences | $1.87 | +6.86% | −56.21% | −58.44% |
| CUE | Cue Biopharma, Inc. | $28.85 | −4.63% | +185.36% | +16.42% |
| MOLN | Molecular Partners AG | $4.45 | +16.19% | +5.45% | +18.67% |
| MENS | Jyong Biotech Ltd. | $2.24 | −6.28% | −34.31% | −95.62% |
| KZIA | Kazia Therapeutics Limited | $14.60 | +15.05% | +192.00% | +86.94% |
| OKUR | OnKure Therapeutics, Inc. | $3.80 | −3.80% | +28.38% | +35.71% |
| ASRT | Assertio Holdings Inc | $23.50 | 0.00% | +157.11% | +103.46% |
| INDP | Indaptus Therapeutics, Inc. | $1.14 | −34.10% | −58.39% | −82.19% |
| HURA | TuHURA Biosciences, Inc. | $2.13 | 0.00% | +184.00% | −26.55% |
| ADCT | ADC Therapeutics SA | $1.05 | −5.41% | −70.17% | −67.39% |
| BDTX | Black Diamond Therapeutics, Inc. | $2.27 | +28.98% | −8.84% | −20.91% |
| LIXT | Nomad Power Solutions Inc | $4.18 | −5.64% | +8.85% | +22.22% |
| GNLX | Genelux Corporation | $2.73 | −6.51% | −40.00% | −25.00% |
| ANIX | Anixa Biosciences, Inc. | $3.61 | +2.41% | +14.08% | +22.20% |
| NTHI | NeOnc Technologies Holdings, Inc. | $4.56 | +30.66% | −48.65% | −29.30% |
| ONCY | Oncolytics Biotech Inc. | $0.86 | +8.30% | −12.69% | −19.28% |
| HBP.TO | Helix BioPharma Corp. | 1.94 CAD | +33.79% | −19.17% | +46.97% |
| AMAN | Amanat Acquisition Corp | $10.70 | +5.42% | +6.89% | +6.89% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.